Revance Therapeutics Inc call shares owned by Group One Trading
Quarter-by-quarter ownership of Revance Therapeutics Inc call shares owned by Group One Trading
from 13F filings
Historical chart of Group One Trading investment in Revance Therapeutics Inc call
Tip: Access up to 7 years of quarterly data
All positions including Revance Therapeutics Inc call held by Group One Trading consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Quarterly reported holdings in Revance Therapeutics Inc call by Group One Trading
| Quarter filed | Position value | Share count | Share price at filing |
|---|---|---|---|
| 2024-09-30 | $407k | 79k | 5.19 |
| 2024-06-30 | $358k | 139k | 2.57 |
| 2024-03-31 | $819k | 167k | 4.92 |
| 2023-09-30 | $710k | 62k | 11.47 |
| 2023-06-30 | $921k | 36k | 25.31 |
| 2023-03-31 | $647k | 20k | 32.21 |
| 2022-12-31 | $877k | 48k | 18.46 |
| 2022-09-30 | $3.7M | 136k | 27.00 |
| 2022-06-30 | $366k | 27k | 13.81 |
| 2022-03-31 | $388k | 20k | 19.50 |
| 2021-12-31 | $263k | 16k | 16.34 |
| 2021-09-30 | $1.4M | 49k | 27.87 |
| 2021-06-30 | $234k | 7.9k | 29.62 |
| 2021-03-31 | $45k | 1.6k | 28.13 |
| 2020-12-31 | $1.0M | 36k | 28.35 |
| 2020-09-30 | $121k | 4.8k | 25.21 |
| 2020-06-30 | $259k | 11k | 24.43 |
| 2020-03-31 | $104k | 7.0k | 14.86 |
| 2019-12-31 | $8.0k | 500 | 16.00 |
| 2019-09-30 | $434k | 33k | 12.99 |
| 2019-03-31 | $8.0k | 500 | 16.00 |
| 2018-12-31 | $8.0k | 400 | 20.00 |
| 2018-09-30 | $492k | 20k | 24.85 |
| 2018-06-30 | $307k | 11k | 27.41 |
| 2018-03-31 | $191k | 6.2k | 30.81 |
| 2017-12-31 | $686k | 19k | 35.73 |
| 2017-09-30 | $8.0k | 300 | 26.67 |
| 2017-06-30 | $8.0k | 300 | 26.67 |
| 2017-03-31 | $8.0k | 400 | 20.00 |
| 2016-09-30 | $2.0k | 100 | 20.00 |
| 2016-06-30 | $29k | 2.1k | 13.81 |
| 2016-03-31 | $38k | 2.2k | 17.27 |
| 2015-12-31 | $243k | 7.1k | 34.23 |
| 2015-09-30 | $193k | 6.5k | 29.69 |
| 2015-06-30 | $176k | 5.5k | 32.00 |
| 2015-03-31 | $87k | 4.2k | 20.71 |
Top funds holding Revance Therapeutics Inc call
View all funds holding Revance Therapeutics Inc call